Here is an interesting article from the Inside MS magazine about some new advances in the treatment of the disease.
A mere 20 years ago, physicians had little besides sympathy to offer to someone just diagnosed with multiple sclerosis. The situation was not without hope: experimental drugs were in development. But no one knew when a reliable treatment would become available.
In the 1990s, clinical trials, enhanced by developments in imaging techniques such as MRI, proved the safety and efficacy of the first disease-modifying drugs, interferon beta-1a (Avonex) and -1b (Betaseron) and glatiramer acetate (Copaxone). The FDA approved them for use by people with relapsing MS. For the first time in history, at least some people with MS were empowered with options for treatment.
The 2000s brought more options. Mitoxantrone (Novantrone) was approved for people with some worsening forms of MS in 2000, and Rebif, another form of interferon beta-1a, was approved in 2002. Last year natalizumab (Tysabri), the first monoclonal antibody available for the treatment of MS (see MABs, page 18) was re-released to market for relapsing forms of MS after an earlier set-back.
As the 2010s beckon, still more treatment possibilities are being rigorously tested around the world. They range from drugs that more precisely target immune system problems to treatments that may repair some of the damage MS has already done. More than 130 clinical trials are in progress, while other experimental drugs are in earlier stages of development.
What follows are just a few of the treatments targeting the MS disease process in the pipeline. Others being tested include treatments for many MS symptoms, as well as rehabilitation techniques to help people with MS lead fuller lives.
Read the entire article: